Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04842812
PHASE1

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Sponsor: Second Affiliated Hospital of Guangzhou Medical University

View on ClinicalTrials.gov

Summary

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Official title: Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2021-01-01

Completion Date

2035-01-01

Last Updated

2024-06-25

Healthy Volunteers

No

Interventions

BIOLOGICAL

TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3

TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.

Locations (1)

Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, China